Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated by Park, Soo-Yeon et al.
RESEARCH Open Access
Gefitinib radiosensitizes non-small cell lung
cancer cells through inhibition of ataxia
telangiectasia mutated
Soo-Yeon Park
1,2, Young Mee Kim
1,2, Hongryull Pyo
1,2*
Abstract
Purpose: Inhibitors of epidermal growth factor receptor (EGFR) have shown dramatic results in a subset of patients
with non-small cell lung cancer (NSCLC), and have also been shown to enhance the effect of ionizing radiation (IR).
We investigated how gefitinib, an orally given EGFR inhibitor for NSCLC patients, can radiosensitize NSCLC cells.
Experimental Design and Results: In clonogenic survival assays performed in three NSCLC cell lines, gefitinib
radiosensitized NCI-H460 and VMRC-LCD but not A549 cells. Gefitinib pretreatment induced multinucleated cells
after IR exposure in NCI-H460 and VMRC-LCD, but not in A549 cells. Gefitinib also inhibited activation of ataxia
telangiectasia mutated (ATM) after IR-exposure in NCI-H460 and VMRC-LCD, but not in A549 cells. An ATM specific
inhibitor increased IR-induced multinucleated cells in both NCI-H460 and A549 cells. Gefitinib pretreatment
inhibited the gradual decrease of gH2AX foci relative to time after IR exposure in NCI-H460 but not in A549 cells.
Suppression of COX-2 in A549 cells induced multinucleated cells and caused radiosensitization after gefitinib+IR
treatment. In contrast, COX-2 overexpression in NCI-H460 cells attenuated the induction of multinucleation and
radiosensitization after the same treatment.
Conclusions: Our results suggest that gefitinib radiosensitizes NSCLC cells by inhibiting ATM activity and therefore
inducing mitotic cell death, and that COX-2 overexpression in NSCLC cells inhibits this action of gefitinib.
Background
Lung cancer is the leading cause of cancer-related
deaths in men and women worldwide [1], and about
80% of lung cancers are non-small cell lung carcinoma
(NSCLC). The 5-year survival rate of patients with
NSCLC remains among the lowest of all major human
cancers at less than 15% [2]. Obviously, novel therapeu-
tic strategies to improve survival of patients with
NSCLC are needed. Epidermal growth factor receptor
(EGFR) has been regarded as an attractive target mole-
cule for the treatment of various cancers including
NSCLC. Recently developed inhibitors of this molecule
have shown dramatic results in a subset of patients with
NSCLC and have become a routinely applied anticancer
agent for this subset of patients [3-5].
EGFR belongs to the ErbB family of plasma membrane
receptor tyrosine kinases and controls many important
cellular functions. Increased EGFR expression has been
observed in many experimental cancer cell lines and
human tumors, including NSCLC, and it has been asso-
ciated with advanced tumor stage, metastasis, and poor
prognosis. Previous studies have suggested that high
expression of EGFR is associated with resistance to can-
cer therapy, including radiation therapy [6,7]. Conver-
sely, EGFR inhibitors have been shown to enhance the
effects of ionizing radiation (IR) [8-12], although the
effective subset of tumors for radiosensitization by these
agents has not yet been defined.
Radiation therapy remains an important part of the
treatment regimen for NSCLC, especially for patients
with unresectable tumors. The concurrent administra-
tion of radiation therapy and chemotherapy is the first-
choice treatment option for stage III unresectable
NSCLC which makes up over 30% of total NSCLC
patients. However, concurrent chemo-radiation therapy
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any medium, provided the original work is properly cited.is frequently toxic and a significant number of patients
suffer from complications such as radiation esophagitis
and radiation pneumonitis during or after this treatment
[13,14]. Therefore, it may be beneficial in terms of redu-
cing toxicity and enhancing the effect of radiation ther-
apy if we can administer radiation therapy and EGFR
inhibitors concurrently to EGFR-inhibitor-responsive
patients instead of administering concurrent chemother-
apy. However, the precise underlying mechanisms for
the radiosensitizing effect of EGFR inhibitors remained
unclear and needed to be addressed to give the basic
rationale for the radiation/EGFR inhibitor combined
treatment and to further enhance their effects.
In this study, we investigated how gefitinib (ZD1839,
Iressa®), an orally given, small-molecular EGFR tyrosine
kinase inhibitor that is currently used in the clinic for
NSCLC patients [15], can radiosensitize NSCLC cells
in order to understand its mechanism of interaction
with IR.
Results
Gefitinib pretreatment enhances the radiosensitivity of
NCI-H460 and VMRC-LCD, but not A549 cells
In our previous report [11], we showed that gefitinib
pretreatment for 4 h enhanced the effect of IR in two
NSCLC cell lines, NCI-H460 and VMRC-LCD, but not
in A549 cells, also an NSCLC cell line. To further con-
firm the differential radiosensitizing effect of gefitinib
according to cell lines, cells were exposed to 15 μmol/L
gefitinib for a longer period (24 h) to allow enough time
for gefitinib to take action, and then irradiated with 2, 4,
or 6 Gy of IR. As shown in Figure 1A, gefitinib
enhanced radiosensitivity of both NCI-H460 and
VMRC-LCD cells (upper panel), and gefitinib pretreat-
ment for 24 h was more effective than 4 h pretreatment.
In contrast, gefitinib did not radiosensitize A549 cells
even after prolonged preincubation with the drug (lower
panel).
We previously proposed that inhibition of Chk2 phos-
phorylation may be an underlying mechanism for radio-
sensitization by gefitinib [11]. Since Chk2 is one of the
core molecules in the G2 checkpoint which mediates IR-
induced G2 arrest, we examined the effect of gefitinib
on IR-induced G2 arrest. Cells were exposed to 15
μmol/L gefitinib for 48 h, irradiated with 6 Gy of g-
radiation, and then further incubated for the indicated
time points. IR-induced G2-M arrest was decreased by
gefitinib pretreatment compared to IR alone in NCI-
H460 and VMRC-LCD cells at 6 or 12 h after IR expo-
sure. However, the G2-M peak was not further
decreased but was sustained for more than 24 h while
the G2-M peak in IR-alone groups continued to
decrease in both cell lines. In contrast, gefitinib did not
affect the IR-induced G2-M arrest in A549 cells (Figure
1B). These results led us to hypothesize that gefitinib
pretreatment attenuates IR-induced G2 arrest, cells sub-
sequently enter into mitosis due to attenuation of G2
arrest, and the cells that entered into mitosis may be
trapped in this cell cycle phase as a form of mitotic
catastrophe (MC). This phenomenon was seen in NCI-
H460 and VMRC-LCD but not in A549 cells.
Gefitinib pretreatment induces multinucleated cells after
IR exposure
Cancer cells severely damaged by IR are known to
undergo MC or mitotic cell death (MCD) which is char-
acterized by the formation of micronuclei and/or multi-
nuclei [16,17]. At the same time, in mammalian cells
and particularly in cancer cells, MC is mainly associated
with deficiencies in cell cycle checkpoints [18,19]. The
G2-M checkpoint is responsible for blocking mitosis in
the case of damaged DNA, and inhibition or knockout
of proteins that prevent premature mitosis can induce
MC [20]. Therefore, we hypothesized that Chk2 inhibi-
tion and attenuation of IR-induced G2 arrest by gefitinib
may increase IR-induced MC.
To test whether gefitinib pretreatment increases MC
after IR exposure, cells were stained with DAPI to visua-
lize the nuclear morphology after gefitinib plus IR treat-
ment. After gefitinib pretreatment followed by 6Gy IR
exposure, the number of multinucleated cells increased
dramatically in NCI-H460 and VMRC-LCD as com-
pared to IR treatment alone. In contrast, multinucleated
cells were not observed in A549 cells before or after the
same treatment (Figure 2). These findings suggest that
the enhancement of radiosensitivity by gefitinib in the
tested cell lines may have occurred via MC induction.
This MC may have been induced by gefitinib’s inhibition
of G2 checkpoint-related molecules including Chk2.
IR-induced ATM and chk2 phosphorylation are inhibited
by gefitinib pretreatment
The G2 checkpoint is activated in response to IR-
induced DNA double strand breaks, and ATM-Chk2-
Cdc25C-Cdk1/Cyclin B1 is the main cascade in the G2
checkpoint [21,22]. Since we observed that IR-induced
Chk2 phosphorylation was inhibited by gefitinib in our
previous study [11], we tested whether gefitinib pretreat-
ment also inhibits IR-induced activation of ATM
(directly upstream of Chk2) as well. As shown in Figure
3A, IR-induced ATM phosphorylation was almost com-
pletely inhibited by gefitinib pretreatment in NCI-H460
and VMRC-LCD cells but not in A549 cells. Gefitinib
alone did not affect ATM phosphorylation in any of the
three cell lines. The status of Chk2 phosphorylation was
consistent with ATM activity. ATM kinase assay showed
the same results with NCI-H460 and A549 cells (Figure
3B). We confirmed these results with confocal
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Page 2 of 12Figure 1 Clonogenic cell survival and cell cycle regulation after combination treatment of gefitinib and ionizing radiation (IR) in lung
cancer cells. A. Clonogenic cell survival assays after gefitinib plus IR treatment. Cells were treated with gefitinib for 24 h, irradiated with graded
doses of g-radiation, incubated in the drug-containing media for another 48 h, and allowed to form colonies in drug-free medium. Surviving
fractions for radiation+gefitinib were normalized by dividing by the surviving fraction for gefitinib alone. Closed circle, IR + vehicle (DMSO)
treatment; Open circle, IR + 15 μmol/L gefitinib treatment. Error Bars, SE of three independent experiments in triplicate. **, P < 0.01; *, P < 0.05
compared with IR alone group. B, Cell cycle changes after gefitinib plus IR treatment. Cells were treated with 15 μmol/L gefitinib for 48 h and
then irradiated. The cells were harvested after the indicated time points. Each cell cycle phase was measured by flow cytometry. Three
independent experiments were performed and the results were all identical. Presented with a representative figure.
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Page 3 of 12Figure 2 Multinuclei formation after the treatment with gefitinib plus ionizing radiation (IR) in lung cancer cells. A, Nuclear morphology
of NCI-H460 (upper), VMRC-LCD (middle), and A549 (bottom) cells after the gefitinib plus IR treatment. Cells were grown on coverslips and
treated with 15 μmol/L gefitinib for 48 h, and then irradiated with 6 Gy IR. After the indicated times, cells were fixed, stained with DAPI, and
then observed under confocal microscopy (X400 magnification). Multinucleated cells were indicated with arrow. B, The number of
multinucleated cells was counted and plotted. At least 100 cells per sample were counted. Each columns represent the means of three
independent experiments; Error bars, SE.
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recruited to DNA-damaged sites (foci) and participates
in the DNA damage repair process [23]. As shown in
Figure 3C, the number of ATM or Chk2 foci increased
after IR exposure. When cells were pretreated with gefi-
tinib, the numbers of IR-induced ATM and Chk2 foci
were diminished in NCI-H460 and VMRC-LCD cells
compared to those counted after IR exposure alone.
However, gefitinib pretreatment did not change the
number of IR-induced ATM or Chk2 foci in A549 cells.
These results suggest that gefitinib pretreatment inhibits
phosphorylation of ATM as well as that of Chk2 in
NCI-H460 and VMRC-LCD cells, but not in A549 cells.
To test whether another EGFR inhibitor would also
block IR-induced ATM/Chk2 phosphorylation, we per-
formed the same experiments using cetuximab, which is
a monoclonal antibody raised against EGFR. Cetuximab
inhibited EGFR activity almost completely at the tested
concentration (2 mmol/L, data not shown). In the three
cell lines tested, ATM and Chk2 were phosphorylated
immediately after exposure to IR. However, in contrast
to gefitinib, IR-induced ATM and Chk2 phosphorylation
were not inhibited when cells were pretreated with
cetuximab before IR exposure (Additional file 1). This
finding suggests that inhibition of IR-induced ATM-
Chk2 phosphorylation is not a general characteristic of
all EGFR inhibitors but a function specific to gefitinib.
Therefore, this function of gefitinib may be independent
of its inherent EGFR-inhibiting activity.
Gefitinib pretreatment inhibits repair of IR-induced DNA
damage
To test the role of gefitinib pretreatment on IR-induced
DNA damage, we performed immunofluorescent stain-
ing with anti-gH2AX antibody followed by confocal
microscopic evaluation to observe the change in the
number of gH2AX foci, a marker for DNA double
strand breaks, after exposure to IR [24]. In NCI-H460
cells, gH2AX foci were induced immediately after expo-
sure to IR (~30 min), and the number of foci decreased
Figure 3 Gefitinib inhibits ionizing radiation (IR)-induced ATM-Chk2 activation. A, Western blot analyses for ATM and Chk2
phosphorylation. Cells were pretreated with gefitinib or vehicle (DMSO) for 48 h, exposed to 6 Gy IR, and were harvested and lysed for western
blot analysis after 30 min. Blots representative of three independent experiments. B, Cells were harvested, lysed and immunoprecipitated with
ATM antibody followed by in vitro kinase assays using GST-Chk1 as a substrate. The amount of phosphor-Chk1 was assessed by immunoblotting
using phospho-ser345-Chk1 antibody. C, Cells were grown on coverslips, pretreated with gefitinib for 48 h, and then exposed to 6 Gy IR. After 30
min, cells were fixed and stained with anti-pATM and anti-pChk2 antibodies. Costaining with DAPI was done to show the nuclei. pATM (green),
pChk2 (red) and DAPI (blue).
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[25,26] in IR alone-treated groups. In contrast, the
decrease in gH2AX foci according to time after IR-expo-
sure was attenuated in the gefitinib-pretreatment
groups, indicating that gefitinib inhibited the repair pro-
cess of damaged DNA (Figure 4A and 4B, upper panels).
In A549 cells, the pattern of induction and decrease of
gH2AX foci after IR exposure was similar to that seen
in NCI-H460 cells, but gefitinib pretreatment did not
attenuate the decrease of gH2AX foci in A549 cells over
time (Figure 4A and 4B, lower panels). Therefore, the
radiosensitizing effect of gefitinib might be due to inhi-
bition of IR-induced ATM-Chk2 activation, and this
event may affect the repair process for IR-induced DNA
damage in NCI-H460 or VMRC-LCD, but not in A549
cells.
Inhibition of IR-induced ATM phosphorylation causes
multinucleated cell formation in NSCLC cells
The G2 checkpoint is known to play a critical role in
preventing MC and the formation of multinucleated
cells, as discussed previously. We performed additional
experiments to determine whether inhibition of ATM
phosphorylation is the cause of multinucleated cell
induction in NCI-H460 cells after gefitinib plus IR treat-
ment, and whether lack of multinucleated cell formation
in A549 cells after the same treatment is due to intact
IR-induced ATM phosphorylation. We administered a
specific ATM inhibitor, Ku55933, with IR and analyzed
the induction of multinucleated cells in NCI-H460 or
A549 cells. Blocking ATM phosphorylation with
Ku55933 prior to IR exposure increased the number of
multinucleated cells significantly in both NCI-H460 and
A549 cells (Figure 5). These results further suggest that
induction of multinucleated cells by gefitinib plus IR
treatment may be due to inhibition of ATM activity by
gefitinib.
Collectively, gefitinib may radiosensitize NCI-H460
cells by inhibiting ATM phosphorylation and repair of
damaged DNA after IR exposure, and thereby increasing
multinucleated cell formation. In contrast, gefitinib may
not be able to radiosensitize A549 cells because it does
not inhibit IR-induced ATM phosphorylation in these
cells and therefore cannot induce multinucleated cell
formation and MC.
COX-2 expression of lung cancer cells inhibits
radiosensitization by gefitinib
We questioned why A549 cells were resistant to gefiti-
nib’s radiosensitizing function in contrast to NCI-H460
and VMRC-LCD cells. One difference between A549
and NCI-H460 or VMRC-LCD cells is the COX-2
expression level. A549 cells constitutively overexpress
COX-2 while NCI-H460 and VMRC-LCD cells do not.
We previously reported that COX-2-overexpressing cells
showed resistance to gefitinib’s antineoplastic activity
[27]. Therefore, we examined the effect of COX-2
expression on gefitinib+IR-induced multinucleated cell
formation. We confirmed that A549 cells express high
levels of COX-2 while NCI-H460 and VMRC-LCD cells
express only slight amounts of COX-2 protein (Figure
6A). We established a stably-COX-2-overexpressing cell
line from NCI-H460 (H460-COX2, H460-Mock as a
control cell line). We also made a COX-2-knock down
A549 cell line (AS) using a COX-2-specific shRNA vec-
tor with a mock cell line as a control called AN (Figure
6B). Clonogenic assays were performed after gefitinib
plus IR treatment in these COX-2-overexpressing or
-suppressed cell lines. The degree of radiosensitization
by gefitinib was reduced in H460-COX2 cells compared
to H460-Mock cells. Conversely, gefitinib radiosensitized
AS cells while causing no radiosensitization in AN cells
(Figure 6C).
To further test the effect of COX-2 expression on
multinucleated cell formation, the number of multinu-
cleated cells was counted in COX-2-overexpressing or
-suppressed cells after gefitinib plus IR treatment. In
H460-COX2 cells, the number of gefitinib+IR-induced
multinucleated cells was decreased significantly com-
pared to H460-Mock cells (Figure 6D). On the contrary,
an increased number of multinucleated cells was
detected in AS cells compared to AN cells after the
same treatment (Figure 6D). These results suggest that
COX-2 overexpression in NSCLC cells inhibits gefitinib-
induced radiosensitization. Therefore, the lack of radio-
sensitization of A549 cells by gefitinib seems to be due
to COX-2 overexpression.
Discussion
In the current study, we showed that gefitinib, an orally
given EGFR inhibitor that is used currently to treat
patients with NSCLC, can radiosensitize NSCLC cells by
inhibiting ATM activity which would otherwise promote
repair of damaged DNA and prevents MC after IR expo-
sure. Gefitinib inhibited IR-induced ATM phosphoryla-
tion in the two NSCLC cell lines (NCI-H460 and
VMRC-LCD) that were radiosensitized by this agent,
but IR-induced ATM phosphorylation was intact after
gefitinib pretreatment in an NSCLC cell line (A549) that
was not radiosensitized by this drug. Gefitinib also
inhibited repair of DNA double strand breaks and
increased multinucleated cell formation after IR expo-
sure in the two former cell lines while it did not in the
A549 cell line. We additionally showed that an ATM-
specific inhibitor, Ku55933, induced multinucleated cell
formation after IR exposure in both NCI-H460 and
A549 cells. These findings strongly suggest that ATM
inhibition may be a primary underlying mechanism for
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increased MC. Therefore, gefitinib seems to act as a G2
checkpoint inhibitor.
The concentration of gefitinib used in the current
study (15 μmol/L) is considerably higher compared to
the plasma concentrations (100-500 nmole/L) that can
be achieved after oral administration of gefitinib to
patients. However, several pharmacokinetic studies
showed extensive uptake of gefitinib into tumor in ani-
mal experiments and human investigations. Gefitinib
concentrations were 42 fold higher (average tumor con-
centration was 16.7 μmol/L) in breast tumor and 60 fold
higher (average 33.1 μmol/L) in non-small cell lung
tumor than in coincident plasma samples taken from
human cancer patients [28,29]. Therefore, the concen-
tration of gefitinib we used for our experiments can be
achieved in tumor of cancer patients.
After finding this novel function of gefitinib, we were
curious whether this function is shared by other EGFR
inhibitors, and whether it is EGFR activity-dependent.
We used cetuximab, another EGFR inhibitor that is a
monoclonal antibody against the ligand-binding domain
of EGFR, to test whether this agent shows the same
effect as gefitinib. However, cetuximab did not affect the
phosphorylation level of ATM after IR exposure even
though it significantly reduced EGFR activity as well as
Figure 4 gH2AX foci formation after combination treatment of gefitinib and ionizing radiation (IR). A, NCI-H460 and A549 cells were
treated with gefitinib or vehicle for 48 h, exposed to 6 Gy IR, and fixed and stained with anti-gH2AX (green) antibody and DAPI after the
indicated time points. B, Average number of gH2AX foci per cell was counted and plotted. At least 50 cells were counted. Error Bars, SE of three
independent experiments.
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Page 7 of 12Figure 5 Induction of multinucleated cells after the treatment with Ku55933, a specific ATM inhibitor. A, NCI-H460 and A549 cells were
grown on coverslips and treated with 10 μmol/L Ku55933 for 30 min and then exposed to 6 Gy ionizing radiation (IR). After 72 h, cells were
fixed, stained with DAPI, and observed under confocal microscopy (X400). Cells with multinuclei were indicated with arrow. The number of
multinucleated cells was counted and plotted. At least 100 cells were counted and each column represents the means of three independent
experiments. Error bars, SE. B, Western blots after Ku55933 and IR treatment. Cells were pretreated with 10 μmol/L Ku55933 for 30 min, exposed
to 6 Gy IR, and harvested after 30 min. Western blot analysis was done with anti-pATM, anti-ATM, anti-pChk2, anti-Chk2 antibodies. b-Actin was
used as a loading control. Blots representative of three independent experiments.
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gefitinib seems to be specific to this drug. Cetuximab is
also known to radiosensitize mainly head and neck can-
cer cells [30,31], however, the mechanism of radiosensi-
tization may be different from that of gefitinib. We also
investigated whether EGFR activation using epidermal
growth factor (EGF) affects ATM phosphorylation to
test for a possible connection between EGFR and ATM
signaling pathways. However, we did not find elevated
ATM phosphorylation after EGF administration in the
tested cancer cells (data not shown). Lack of ATM-inhi-
biting activity by cetuximab also indicates that gefitinib’s
ATM-inhibiting function is independent of EGFR activ-
ity. Taken together, the ATM-inhibiting activity of gefi-
tinib seems to be specific to this drug and it also seems
to be independent of its inherent EGFR-inhibiting activ-
ity. This may be a characteristic of small molecular inhi-
bitors that frequently targets more than one protein.
EGFR and KRAS mutations are important factors to
predict response to EGFR-tyrosine kinase inhibitors
[32-35]. We analyzed the status of EGFR mutations in
NCI-H460, A549, and VMRC-LCD and these cells were
all EGFR-wild types in exon 18,19,20, and 21
(unpublished data). In addition, according to the pub-
lished data, NCI-H460 and A549 have KRAS mutations,
while VMRC-LCD is a KRAS wild type [36-38]. Since
gefitinib radiosensitized NCI-H460 and VMRC-LCD
cells but not A549, gefitinib’s radiosensitization does not
seem to be related to EGFR or KRAS mutational status.
A drug sensitivity and a radiosensitization by the drug
seem to be mediated by quite different mechanisms.
W ew e r ec u r i o u sa st ow h yA 5 4 9c e l l sc o u l dn o tb e
radiosensitized by gefitinib. This may be an important
issue because defining the subset of tumors that respond
to this drug is a necessary task to make this drug practi-
cal for radiosensitization. We found that COX-2 overex-
pression in A549 cells inhibited the gefitinib’sM C -
inducing activity. Suppression of COX-2 in A549 cells
allowed for the induction of MC and radiosensitization
after gefitinib plus IR treatment, while COX-2 overex-
pression in NCI-H460 cells reduced MC-induction and
the degree of radiosensitization achieved with same treat-
ment (Figure 6). These results show that COX-2 overex-
pression in NSCLC can play a critical role, although it
may not be the only factor, in the development of resis-
tance to gefitinib’s radiosensitizing activity.
Figure 6 The effect of COX-2 expression on radiosensitization by gefitinib. Western blot analysis was done using anti-COX-2 antibody in
NCI-H460, VMRC-LCD and A549 cells (A) or H460-Mock, -COX2, AN or AS cells (B). b-Actin was used as a loading control. C, Clonogenic cell
survival assays after gefitinib plus ionizing radiation (IR) treatment in H460-Mock and -COX2, or AN and AS cells. Cells were treated with gefitinib
for 24 h, irradiated, incubated in drug-containing media for another 48 h, and allowed to form colonies in drug-free medium. Surviving fractions
for radiation + gefitinib were normalized by dividing by the surviving fraction for gefitinib alone. Error Bars, SE of three independent experiments
in triplicate. *, P < 0.05 compared with IR alone group. D, Multinucleated cell induction after gefitinib plus ionizing radiation (IR) treatment in
H460-Mock and -COX2, or AN and AS cells. Cells were grown on coverslips and treated with 15 μmol/L gefitinib for 48 h, and then exposed to 6
Gy IR. After 72 h, cells were fixed, stained with DAPI, and then observed under confocal microscopy (X400). Cells with multinuclei were indicated
with arrow. The number of multinucleated cells was counted and plotted. At least 100 cells were counted and each column represents the
means of three independent experiments. Error bars, SE.
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is currently unclear. Recently, we reported that COX-
2 overexpressing cancer cells upregulate ataxia telan-
giectasia and rad3-related (ATR) expression and
activity, and that upregulated ATR induces resistance
to DNA damaging agents such as IR or hydroxyurea
[39]. Therefore, upregulated ATR activity in COX-2
overexpressing cancer cells may compensate for the
ATM activity inhibited by gefitinib, and thereby pre-
vent MC. On the other hand, COX-2 may directly
recover gefitinib-inhibited ATM phosphorylation
using as yet undefined mechanisms. Further investi-
gation is warranted to understand the precise
mechanisms involved in the resistance to gefitinib
induced by COX-2.
Conclusions
In conclusion, we propose that gefitinib radiosensitizes
NSCLC cells through inhibiting IR-induced ATM activa-
tion, and therefore acts as a G2 checkpoint inhibitor to
induce mitotic catastrophic cell death. COX-2-over-
expressing cells show resistance to gefitinib’s radiosensi-
tizing activity. Our findings may contribute to the
application of gefitinib or other EGFR inhibitors for
combined treatment with radiation therapy in patients
with NSCLC.
Materials and methods
Reagents
Gefitinib was provided by AstraZeneca UK Ltd. (Lon-
don, United Kingdom), Cetuximab was provided by
Merck (Darmstadt, Germany), Ku55933, an ATM kinase
specific inhibitor, was acquired from Calbiochem
(Darmstadt, Germany).
Cell culture
Human lung large cell carcinoma cell line NCI-H460
and human lung adenocarcinoma cell line A549 were
obtained from the American Type Culture Collection
(ATCC, Manassas, VA, USA). Human lung adenocarci-
noma cell line VMRC-LCD was obtained from the Japa-
nese Collection of Research Bioresources (JCRB, Osaka,
Japan). Cyclooxygenase(COX)-2 knocked down A549
cells by RNA interference [40] and COX-2 overexpres-
sing NCI-H460 stable cells have been established as
described previously [41]. All cells were cultured in
RPMI 1640 medium supplemented with 10% fetal
bovine serum (FBS, Hyclone, Logan, UT, USA),
2 mmol/L glutamine, 50 units/ml penicillin, and 50 μg/
ml streptomycin (Life Technologies, Gaithersburg, MD,
USA) at 37°C in an atmosphere of 5% CO2 and 95% air.
All cell lines were qualified for mycoplasma contamina-
tion using MycoAlert® Mycoplasma detection kit (Lonza,
Rockland, ME, USA).
Clonogenic assay
The effectiveness of the combined treatment with gefiti-
nib and IR was assessed by clonogenic survival assays as
described previously [40]. The surviving fraction (SF) of
cells exposed to gefitinib plus IR was normalized by
dividing by the SF of gefitinib alone.
Flow cytometry
To analyze cell cycle, 1.5 ~ 3 × 10
5 cells were plated into
60 mm dishes for the determination of each data point.
After 24 h, the cells were exposed to the appropriate con-
centrations of gefitinib or vehicle (DMSO) for 48 h, and
then exposed to 6 Gy of g-rays using the Gammacell
3000 Elan system (MDS Nordion Inc., Ontario, Canada).
Cells were further incubated in media which contained
either the drug or the vehicle for the indicated times. The
cells were trypsinized (retaining all floating cells), fixed
with 70% ethanol at 4°C overnight, washed with phos-
phate buffered saline (PBS), then incubated with 50 μg/
ml of propidium iodide (PI; Sigma, St. Louis, MO, USA)
and 5 μg/ml of RNase A (Amresco, Solon, OH, USA) at
room temperature for 0.5 h. The number of cells at each
cell cycle was evaluated with the FACS Calibur system
(Becton Dickinson, San Jose, CA, USA).
Immunofluorescence and confocal microscopy
Cells were grown on coverslips, treated with 15 μmol/L
gefitinib or vehicle (DMSO) for 48 h and then exposed
to 6 Gy of g-rays. After incubation in CO2 incubator,
cells were washed with PBS and fixed with 4% parafor-
maldehyde for 20 min and permeabilized in 0.5% Triton
X-100 for 15 min. Anti-phosphor-ataxia telangiectasia
mutated (ATM) monoclonal antibody (Rockland, Gil-
bertsville, PA, USA), anti-phosphor-checkpoint kinase 2
(Chk2) polyclonal antibody (Cell Signaling Technology,
Beverly, MA, USA) or g-H2AX monoclonal antibody
(Millipore, Billerica, MA, USA) were diluted (1:500), and
incubated with cells for overnight at 4°C. Samples were
then incubated for 1 h at room temperature with Alexa
488 anti-mouse and Alexa 594 anti-rabbit secondary
antibodies (Molecular Probes, Eugene, OR, USA).
Nuclear staining was done with 4’,6-diamidino-2-pheny-
lindole dihydrochloride (DAPI) (Wako, Osaka, Japan).
Cells were washed and mounted using mounting solu-
tion (Dako, Denmark). The images were taken with
confocal microscopy (Carl Zeiss, Germany).
Immunoblotting
Harvested cells were used for immunoblotting as
described previously [40]. Equal amounts of protein
were analyzed in triplicate by SDS-polyacrylamide gel
electrophoresis. The following antibodies were used;
anti-phosphor-Ser1981-ATM (Rockland), anti-phosphor-
Thr68-Chk2 (Cell Signaling), anti-ATM (Novus,
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anti-b-Actin (Sigma) antibodies. Immunoreactive pro-
teins were detected with secondary antibodies and visua-
lized using an enhanced chemiluminescence detection
system (Amersham Bioscience, Piscataway, NJ, USA).
In vitro kinase assay for ATM
Cells were lysed in lysis buffer (10 mM Tris-HCl pH 7.4,
1.0% Triton X-100, 0.5% Nonidet P-40, 150 mM NaCl, 20
mM sodium fluoride, 0.2 mM sodium orthovanadate, 1.0
mM EDTA, 0.2 mM PMSF). The cell lysates were centri-
fuged at 15,000 g for 20 min at 4°C to remove cell debris.
Equal amounts of protein were incubated with anti-ATM
(Novus) antibody for overnight. After addition of Protein
A-agarose (Santa Cruz Biotechnology), the lysates were
incubated for an additional 4 h. The beads were washed
twice with the lysis beffer, once with the kinase beffer
(10 mM Tris-HCl pH 7.4, 150 mM NaCl, 10 mM MgCl2,
0.5 mM DTT), and then incubated with kinase buffer that
contains 1 mM ATP, 1 ug Chk1 kinase protein (Cell sig-
naling) as a substrate for 20 min at 37°C. After incubation,
the beads were boiled for 5 min with 5× concentrated
electrophoresis sample buffer to terminate the reaction.
The supernatants were separated by SDS-PAGE, and
immunoblotted with ATM (Novus), Chk1, pSer345 Chk1
(Cell signaling) antibodies. Immunoreactive proteins were
detected with secondary antibodies and visualized using
an enhanced chemiluminescence detection system
(Amersham Bioscience, Piscataway, NJ, USA).
Statistical analysis
Statistical significance was examined using Student’s
t-tests. The two-sample t test was used for two-group
comparisons. Values were reported as means ± standard
errors (SE). P values < 0.05 were considered significant.
Additional material
Additional file 1: Cetuximab does not inhibit ionizing radiation (IR)-
induced ATM-Chk2 activation. Western blots for ATM and Chk2
phosphorylation after IR exposure with or without cetuximab
pretreatment. Cells were pretreated with cetuximab or vehicle for 48 h,
exposed to 6 Gy IR, and were harvested and lysed for western blot
analysis on indicated time point. Blots representative of three
independent experiments.
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